

Supplementary Materials: Isolation and Biosynthetic Analysis of Haliamide, a New PKS-NRPS Hybrid Metabolite from the Marine Myxobacterium *Haliangium ochraceum*

Yuwei Sun ¹, Tomohiko Tomura ¹, Junichi Sato ¹, Takashi Iizuka ², Ryosuke Fudou ³ and Makoto Ojika ^{1,*}




Figure S1. Cont.





Figure S1. Feeding experiments with stable isotope labeled precursors. (a) ^{13}C -NMR spectrum (100 MHz) of $[1,2\text{-}^{13}\text{C}_2]$ acetate-labeled haliamide in CDCl_3 ; (b) ^{13}C -NMR spectrum (100 MHz) of $[1\text{-}^{13}\text{C}]$ propionate-labeled haliamide in CDCl_3 ; (c) ^{13}C -NMR spectrum (100 MHz) of DL- $[1\text{-}^{13}\text{C}]$ alanine-labeled haliamide in CDCl_3 ; (d) ^{13}C -NMR spectrum (100 MHz) of $[1\text{-}^{13}\text{C}]$ benzoic acid-labeled haliamide in CDCl_3 .



Gene	Protein	Length (aa)	Type	Domain position
<i>hlaA</i>	HlaA	4183	NRPS-type I PKS	C (11-293), A (477-861), PCP (944-1009), KS ₁ (1023-1448), DH ₁ (1482-1641), KR ₁ (1923-2086), ACP ₁ (2175-2245), KS ₂ (2266-2690), AT (2793-3081), DH ₂ (3148-3299), KR ₂ (3779-3956), ACP ₂ (4057-4128)
<i>hlaB</i>	HlaB	3045	Type I PKS	KS ₁ (31-447), AT (550-840), ER (1131-1433), KR (1447-1616), ACP ₁ (1709-1775), KS ₂ (1793-2205), ACP ₂ (2366-2430)

Figure S2. Detailed annotation of PKS and NRPS by antiSMASH 3.0 analysis. The annotation of HlaA and HlaB revealed 5 modules (1 NRPS and 4 PKSs), while several domains of PKSs are thought to be missing considering the structure of haliamide (1). These domains are AT domains in module 2 and 5, DH in module 4 and KR domain in module 5.

> HlaA_AT (module 3)
 FPGQGAQWAGMARELYAREPAFRDALKACDRAIRDEAEWSLIAWLHGEGEAERIDRIQPALFAV
 MVSLAGLWRDWGYEPAEVVGHSGQGEVAAAYVAGALSLEDAVAIIVRRSAMLRLTSLGRGAMMVV
 ELTADKAAERIESVRDRVAVAVVNGPRSVVLSGDVEALETGAELEAEGVYQRFVKVDVVASHSPQ
 MDPIRAKLLGALSEIAPQRGTTPIRSTVSTRTISGEEMDADYWWSNLRRPVRFGAVVEAMAQER
 DILFLEISAHPLLRPAVEEQAPGRAVSSLRR

(underline: methylmalonate-specific motif)

> HlaB_AT (module 4)
 LFTGQGAQRADMGRGLYEHHPGFRETLDRCADALGRAHDLREVMWSSDGRDLRTGWTQPALF
 ALEVSLAALWRQWGIEPEVLVGHVSGEIAAACVAGVFSIEDGMRLVEARARLMDALPEGGAMVA
 VRGQPARIERAVASAEGVSVAAFNGPDQVVISGASDAVQALASELAEAGLRAKALTVSHAFHSEL
 MEPMLEDFRAALRDIRFHPPPLVSNLREGELAGPEVASADYWEHVRAPVRFLEGMRAAHAVG
 VDHYLEIGPQPVLRCRLGATCVPAGGGETWLPSSLQR

(underline: malonate-specific motif)

> Hoch_5652 (possible *trans*-AT)
 MGTALLFPGQGSQKVGMGKALVDAFPAARAVFDEADEALGFAISEVCFEGPADKMLTAYSQPAI
 LTQSI AVLRAAQAEGRIAQDGEVVAAMGHSLGEFTALVAAGFTLSDAVRLVHLRGQAMQDAVPM
 GEGGMAALLGLDAEAVQALCDEVAEQVCVPANLNGAGQVVISGHAGAIERAVAAAKGKGAKR
 AIKLQVSAPFHSPLMQPAAERLAEALDGAIEPLRVPVISNVEAAPNSDAGRVKELLVAQVTGAVR
 WEESMHALAAMDVVSQGFEGAGKVLRLGLFSRTVKELPVHSLSEPDDIREGSNERGD

(underline: malonate-specific motif)

Figure S3. Sequence of AT domains.





Figure S4. Phylogenetic tree of AT domains of type I PKS from several bacterial metabolites. Thirty three sequences from actinobacteria and proteobacteria were used, including AT domains in the amphotericin B (*amph*), ansamitocin (*asm*), avermectin (*ave*), epothilone (*epo*), erythromycin (*ery*), haliamide (*hla*), nystatin (*nys*), rapamycin (*rap*), soraphen (*sor*) and stigmatellin (*sti*) biosynthetic gene cluster. The AT domains from *hla* cluster are indicated by red underline. The AT domain of module 3 in *hlaA* is grouped in the methylmalonate specific clade, while AT domain of module 4 in *hlaB* is grouped in the malonate specific clade.

a



b





Figure S5. Cont.

c



d





Figure S5. Cont.

e



f





Figure S5. Cont.

g



h




Figure S5. Cont.




Figure S5. Spectra of haliamide (**1**). (a) ^1H -NMR (400 MHz, CDCl_3); (b) ^{13}C -NMR (100 MHz, CDCl_3); (c) HMQC; (d) HMBC; (e) NOESY; (f) DQF-COSY; (g) UV; (h) IR; (i) ESI-MS.




Figure S6. Cytotoxicity of haliamide (**1**) against HeLa-S3 cells. Markers indicate average values with SE ($n = 4$), and the lines indicate theoretical sigmoid curves ($y = 100/(1 + e^{-a(x - b)})$, $x: \log(\mu\text{M})$). Paclitaxel is a positive control ($\text{IC}_{50} = 8.9 \text{ nM}$).